JM Research Investigación Médica
Dra. Mercedes Paredes Paredes MsC
Professional Experience
General Director
JM Clinical Trial Research Center, Houston, Texas, USA.
April 2025 – Present
General Director
JM Research Clinical Research Center Mexico, Cuernavaca, Morelos, Mexico.
July 2024 – Present
Researcher at JM Research Clinical Research Center.
General Director
JM Research High Specialty Laboratory, Cuernavaca, Morelos, Mexico.
July 2019 – Present
Researcher
JM Research Clinical Research Center Mexico, Cuernavaca.
July 2019 – 2024
General Director and Researcher
JM Research Clinical Research Center, Cuernavaca, Morelos, Mexico.
July 2013 – 2019
Project Manager
Center for Infectious Diseases, School of Public Health, University of Texas at Houston.
September 2008 – May 2011
Study Coordinator
Center for Infectious Diseases, School of Public Health, University of Texas at Houston.
September 2006 – October 2007
Attending Physician of Internal Medicine
Regional Hospital No. 72, IMSS Tlalnepantla, State of Mexico, Mexico.
April 2004 – March 2005
Attending Physician of Internal Medicine
Central North Hospital, PEMEX. Mexico City, Mexico.
December 2004 – September 2005
Attending Physician of Internal Medicine
Satellite Hospital. Naucalpan, State of Mexico, Mexico.
November 2004 – June 2005
Clinical Research Experience
Principal Investigator
Multicenter clinical trial to evaluate resveratrol as an adjuvant to metformin for the management of prediabetes. (2023-2024)
Principal Investigator
International multicenter phase III clinical trial for the treatment (Paxlovid) of COVID-19 in the pediatric population. (2021-Present)
Principal Investigator
Phase 3 clinical study of vaccine for COVID-19 in adults. (2022 – 2025)
Sub-Investigator
Phase 3 clinical study of vaccine for Respiratory Syncytial Virus in the pediatric population. (2020 – 2022)
National Coordinator
Phase 2 protocol of anti-infectious gel for the prevention of infection of post-surgical and traumatic wounds. (2019)
Principal Investigator
Phase 3 clinical study of treatment for Diabetes Mellitus in children and adolescents. (2017- 2024)
Principal Investigator
Phase 3 clinical study of influenza vaccine in the pediatric population, Mexico. (2017-2018)
Principal Investigator
Phase 4 clinical study of treatment for Mixed Dyslipidemia. (2017-2018)
Principal Investigator
Phase 4 clinical study of vaccine against Dengue. JM Research, Cuernavaca, Mexico. (2017-2023)
Principal Investigator
Phase 4 clinical study of treatment for Hepatitis C. JM Research, Cuernavaca, Mexico. (2017-2020)
Principal Investigator
Phase 3 clinical study of a treatment for Systemic Arterial Hypertension. JM Research, Cuernavaca, Mexico. (2016-2017)
Principal Investigator
Phase 3 clinical study of a vaccine candidate for Clostridium difficile toxoid for subjects at risk of C. difficile Infection. JM Research, Cuernavaca, Mexico. (2015-2017)
Principal Investigator
Phase 3 clinical study of Dolutegravir or Efavirenz for the treatment of HIV co-infection with Tuberculosis. JM Research, Cuernavaca Mexico. (2015)
Principal Investigator
Phase 3 clinical study with Rifamycin SV-MMX vs Ciprofloxacin in Acute Traveler’s Diarrhea. JM Research, Cuernavaca Mexico. (2015)
Principal Investigator
Phase 3 clinical study of Favipiravir to treat uncomplicated Influenza. Cuernavaca Mexico. (2014)
Principal Investigator
Multicenter phase 3 clinical study to evaluate the efficacy of the traveler’s diarrhea vaccination system. University of Texas at Houston, Cuernavaca Mexico. (2008-2009)
Principal Investigator
Phase 3, multicenter clinical study with Prulifloxacin for the treatment of traveler’s diarrhea. University of Texas at Houston, Cuernavaca, Mexico. (2008)
Sub-investigator
Multicenter phase 2 clinical study for the use of an E. coli vaccine for the prevention of traveler’s diarrhea. University of Texas at Houston, Cuernavaca, Mexico. (2006-2007)
Sub-investigator
Phase 3 clinical study, multicenter clinical study with Prulifloxacin for the treatment of traveler’s diarrhea. University of Texas at Houston, Cuernavaca, Mexico. (2006-2007)
Sub-investigator
Phase 3, multicenter clinical study with Raptiva to treat patients with moderate to severe psoriasis. Petróleos Mexicanos, Central North Hospital, Mexico City. (2002-2003)
Social Service as Clinical Research Assistant
Department of Immunology and Rheumatology. National Institute of Nutrition and Medical Sciences Salvador Zubirán.
Project Title: Prevalence of cervical lesions in Patients with Systemic Lupus Erythematosus.
Clinical Education and Training
Clinical Fellowship in Infectious Diseases
University of Texas at Houston, Health Science Center, School of Medicine. Houston, Texas USA.
July 2011 – June 2013
Clinical Rotation (Observership)
Infectious Diseases. Memorial Hermann Hospital. University of Texas at Houston, Health Science Center. Houston, Texas USA.
June 2011
Infection Control Fellow Course
Infectious Disease Society of America.
September 30, 2011
ACLS Provider Certification
Kelsey Seybold, Houston Texas, USA.
June 2011
Certification from the Educational Commission for Foreign Medical Graduates of the United States
0-663-807-6.
December 6, 2007
Clinical Rotation (Observership)
Critical and Pulmonary Medicine. Northwestern Memorial Hospital. Northwestern University’s Feinberg. School of Medicine. Chicago, Illinois USA.
September 2003
Clinical Rotation (Observership)
Infectious Diseases. MD Anderson Cancer Center. University of Texas at Houston. Houston, Texas USA.
May 2008
Specialty in Internal Medicine
Internal Medicine. National Autonomous University of Mexico, PEMEX Central North Hospital. Mexico City, Mexico.
Professional License: 4011641
March 2000 – February 2004
Advanced Trauma Life Support Student Course (ATLS)
Approved by the American College of Emergency Physicians and the American College of Surgeons.
1999
Social Service
Department of Immunology and Rheumatology. National Institute of Nutrition and Medical Sciences Salvador Subirán.
Research Project: Prevalence of cervical lesions in Patients with Systemic Lupus Erythematosus.
July 1998 – February 1999
General Medicine
National Autonomous University of Mexico, Iztacala campus. Tlalnepantla, State of Mexico, Mexico.
Professional License: 3481676
July 1994 – June 1997
Research Education and Training
Diploma in Hospital Administration and Innovation
Faculty of Medicine UNAM, FUNSALUD, Mexico City, Mexico.
2024 – Present
Specialty in Person-Centered Approach
Gestalt Institute, Cuernavaca, Morelos, Mexico.
2021 – 2023
Master of Science in Commercialization of Science and Technology
University of Texas at Austin/CGIE, CIMAV, Monterrey Mexico.
July 2016 – 2017
Research Fellowship in Infectious Diseases
University of Texas at Houston, Houston, Texas, USA.
November 2007 – August 2008
Clinical Research Curriculum
Center for Clinical Research and Evidence-Based Medicine. University of Texas Health Science Center at Houston. Houston, USA.
Accredited Courses: Intro to Clinical Research, Clinical Trial Design, Career Development Seminar, Health Services Research, Clinical Research Design Workshop, Scientific Writing, Biostatistics for Clinical Investigators, Literature Appraisal, Navigating NIH, Ethical Aspects of Clinical Research, Introduction to Translational Research.
2007 – 2009
Good Clinical Practices
Pfizer 2017, Boehringer Ingelheim 2019, Transcelerate 2024.
Clinical Trial Standard Operation Procedures
Developing for Compliance and Usability. Center for Clinical and Translational Research. University of Texas at Houston, Houston, Texas, USA.
November 2008
Protecting Human Research Subjects in Biomedical and Genetics Research
University of California at Los Angeles.
April 2008
Human Participant Protections Education for Research Teams
National Cancer Institute, USA.
April 2006
Publications of Scientific Articles in International Journals
Mechanisms of infection by SARS-CoV-2, infammation and potential links with the microbiome.
Future Virology
16(1), 43–57 (2021).
Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial.
Hum Vaccin Immunother.
2020 Jun 2;16(6):1380-1384.
Remuneration in the United States and Mexico: Assessing the level of influence on potential clinical research participants about their decision to participate in a clinical trial and the risk of fraud.
Clinical Ethics
2018 Jan 13 (2).
Urinary IL-8 as an Early Diagnostic Tool for Nosocomial Urinary Tract Infection.
Medical Science and Technology
2017 May 58(7): 15-20
Persistent abdominal symptoms in US adults after short-term stay in Mexico.
J Travel Med.
2014 May-Jun;21(3):153-8
Efficacy and safety of a patch vaccine containing heat-labile toxin from Escherichia coli against travellers’ diarrhoea: a phase 3, randomised, double-blind, placebo-controlled field trial in travellers from Europe to Mexico and Guatemala.
Lancet Infect Dis.
2014 Mar;14(3):197-204
Genetic polymorphisms in serotonin transporter and G-protein genes in patients with irritable bowel syndrome.
Gastroenterology
2012, 142(5):S562.
Interleukin 10 (IL-10) in Susceptibility and Pathogenesis of Irritable Bowel Syndrome (IBS),
American Journal of Gastroenterology:
October 2011 – Volume 106 – Issue – p S161
Advances in the Treatment of Travelers’ Diarrhea.
Curr Gastroenterol Rep
2011; 13: 402-7.
A Randomized, Double-Blind, Study of Rifaximin 550mg vs. Placebo in the Prevention of Travelers’ Diarrhea in Mexico during the Dry Seasons.
J Travel Med.
2011; 18:333-6.
Campylobacter jejuni is Not an Important Pathogen as a Cause of Travelers’ Diarrhea in U.S. Travelers to Mexico.
J Travel Med
2011; 18: 56-8.
Seasonality of Diarrheagenic Eschericha coli pathotypes in U.S. Students Acquiring Diarrhea in Mexico.
J Travel Med.
2011; 18: 121-5.
Biochemical and Genetic Diversity of Enterotoxigenic Escherichia coli Associated with Diarrhea in United States Students in Cuernavaca and Guadalajara, Mexico, 2004-2007.
J Infect Dis
2010; 201: 1831-8.
Whole Blood Interferon Gamma (IFN-alpha) Response to Cholera Toxin B Subunit and Resistance to Travelers’ Diarrhea. A Pilot Study of Cellular Immune Response in Enterotoxigenic Escherichia coli Associated Diarrhea.
Clin Vac Imm
2010; 17: 879-81.
Influence of Host Interleukin-10 Polymorphisms on Development of Traveler’s Diarrhea Due to Heat-Labile Enterotoxin-Producing Escherichia coli in Travelers from the United States Who Are Visiting Mexico.
Clin Vac Imm
2008; 15: 1194-8.
Enterotoxigenic Escherichia coli Heat-Labile Toxin Seroconversion in US travelers to Mexico.
J Travel Med
2008; 3: 156-61.
Academic Affiliations
Member, Academy of Medicine
Universidad Latinoamericana
2020
Lecturer, Basic Immunology course for the General Physician program
Universidad Latinoamericana
2nd Semester 2001-1
Lecturer, Practical Infectology course for the General Physician program
Universidad Latinoamericana
8th Semester 2020-2
Book Chapters
[Cephalosporins].
In: Espinosa-López FR, ed. Therapeutics in Infectious Diseases. Mexico: Grupo M y M,
ISBN 978-607-97533-1-3. 1st digital edition. 2019: 650-660.
[New Antimicrobial Agents].
In: Espinosa-López FR, ed. Therapeutics in Infectious Diseases. Mexico: Grupo M y M,
ISBN 978-607-97533-1-3. 2019: 484-494.
[Therapeutics and Vaccines Against Pathogenic Escherichia coli].
In: Torres A, E. coli in the Americas. Springer,
ISBN 978-3-319-45091-9, 2016: 251-280.
[Cephalosporins].
In: Espinosa-Lopez FR, ed. Therapeutics in Infectious Diseases. Mexico: Grupo M y M,
ISBN 967-607-95532-9-0. 2012: 511-21.
[New Antimicrobial Agents].
In: Espinosa-López FR, ed. Therapeutics in Infectious Diseases. Mexico: Grupo M y M,
ISBN 967-607-95532-9-0. 2012: 367-74.
[Bioterrorism, Clinical Evaluation and Therapeutic Management].
In: Espinosa-López FR, ed. Therapeutics in Infectious Diseases. Mexico: Grupo M y M,
ISBN 968-5157-08-0. 2008: 269-78.
[New Antimicrobial Agents].
In: Espinosa-López FR, ed. Therapeutics in Infectious Diseases. Mexico: Grupo M y M,
ISBN 968-5157-08-0. 2008: 279-88.
[Cephalosporins].
In: Espinosa-López FR, ed. Therapeutics in Infectious Diseases. Mexico: Grupo M y M,
ISBN 968-5157-08-0. 2008: 429-40.